Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBT NASDAQ:BPTH NASDAQ:ENSC NASDAQ:FRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.16-8.1%$3.17$2.11▼$12.60$4.09M-0.03533,785 shs141,041 shsBPTHBio-Path$0.16-1.3%$0.18$0.12▼$3.39$1.30M-0.03988,022 shs38,129 shsENSCEnsysce Biosciences$2.13-1.4%$2.21$1.62▼$14.67$5.05M0.98955,109 shs76,623 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare-8.09%-15.29%-27.15%-39.50%-70.55%BPTHBio-Path-1.27%-7.14%-17.68%-5.45%-91.92%ENSCEnsysce Biosciences-1.39%-1.39%0.00%+21.02%-69.66%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+1.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare1.5583 of 5 stars0.02.00.04.33.81.70.0BPTHBio-Path0.8885 of 5 stars0.05.00.00.00.60.01.3ENSCEnsysce Biosciences0.4603 of 5 stars0.04.00.00.01.00.00.6FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ABPTHBio-Path 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.33M3.07N/AN/A($11.37) per share-0.19BPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AENSCEnsysce Biosciences$5.21M0.97N/AN/A$2.59 per share0.82FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-647.29%N/A-50.13%8/18/2025 (Estimated)BPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)FRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/ALatest BPTH, FRTX, ENSC, and ALBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02N/AN/AN/A$0.67 millionN/A5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.190.19BPTHBio-PathN/A0.860.86ENSCEnsysce BiosciencesN/A2.502.50FRTXFresh Tracks TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%BPTHBio-Path5.74%ENSCEnsysce Biosciences5.63%FRTXFresh Tracks Therapeutics25.04%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%BPTHBio-Path0.72%ENSCEnsysce Biosciences7.90%FRTXFresh Tracks Therapeutics0.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million1.19 millionNot OptionableBPTHBio-Path108.31 million5.73 millionOptionableENSCEnsysce Biosciences102.37 million2.18 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableBPTH, FRTX, ENSC, and ALBT HeadlinesRecent News About These CompaniesFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 26, 2025 | finance.yahoo.comFresh Tracks to cease stock trading as drug company dissolvesFebruary 26, 2025 | bizwest.comBFresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink MarketFebruary 25, 2025 | prnewswire.comFresh Tracks Therapeutics Announces Appointment of Custodian and Planned DistributionJanuary 27, 2025 | finance.yahoo.comFresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of CompanyDecember 6, 2024 | prnewswire.comFresh Tracks Therapeutics (OTC:FRTX) Stock, Short Interest ReportOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics (OTC:FRTX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comFresh Tracks Therapeutics Inc (FRTX)August 31, 2024 | uk.investing.comAjofé Drops “One Time,” a Timeless Track with a Fresh BeatAugust 30, 2024 | thisdaylive.comTFresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of CompanyJune 17, 2024 | globenewswire.comFresh Tracks Therapeutics Inc. (FRTX) Institutional HoldingsMay 25, 2024 | nasdaq.comExploration capital buys fresh tracks therapeutics shares worth over $19kApril 25, 2024 | investing.comExploration capital purchases Fresh Tracks Therapeutics stock worth $2,805April 13, 2024 | investing.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 16, 2024 | finanznachrichten.deFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | finance.yahoo.comFresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15thFebruary 14, 2024 | globenewswire.comFresh Tracks Therapeutics IncJanuary 3, 2024 | morningstar.comMFresh Tracks leaders doubt they have support for liquidationDecember 28, 2023 | bizwest.comBFresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15thDecember 27, 2023 | finance.yahoo.comFresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Listing on OTC Pink MarketDecember 20, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, FRTX, ENSC, and ALBT Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.16 -0.19 (-8.09%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.21 +0.05 (+2.31%) As of 07/18/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Bio-Path NASDAQ:BPTH$0.16 0.00 (-1.27%) As of 07/18/2025 03:34 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Ensysce Biosciences NASDAQ:ENSC$2.13 -0.03 (-1.39%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.12 -0.01 (-0.47%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Fresh Tracks Therapeutics NASDAQ:FRTXFresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
